● Recruiting

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

Condition: Ovarian Cancer · Melanoma · Triple Negative Breast Cancer · Sponsor: Hefei TG ImmunoPharma Co., Ltd.

PhasePhase 1

Planned participants38

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors

This description comes directly from the study's public registry record.

Talk to the study team

Xiaohu Zheng, Doctorate · +86-13956959849 · xiaohu.zheng@tgimmunopharma.com

Hang Zhou, Bachelor · +86-15212434595 · hang.zhou@tgimmunopharma.com

Always discuss trial participation with your own doctor first.

Locations (2)

NEXT Oncology, Dallas	Dallas, Texas, United States	Recruiting
Next Oncology, Virginia Cancer Specialists	Fairfax, Virginia, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05746897